Form 4 for AURA Aura Biosciences, Inc.
Accepted 2026-03-03 00:00:00 ET · period of report 2026-03-02 · accession 0001193125-26-088158 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-03-03 | 2026-03-02 | AURA | Plavsic Mark | CTO | A - Grant | $0.00 | +62.3K | 243.7K | +34% | $0 |
| D | 2026-03-03 | 2026-03-02 | AURA | Plavsic Mark | CTO | A - Grant | $0.00 | +112.7K | 112.7K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-03-02 | A | A | 62,339 | $0.00 | 243,736 | D | — | — | (F1) These shares were acquired pursuant to a restricted stock unit ("RSU") award under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the right to receive one share of the Issuer's Common Stock. These RSUs vest in four substantially equal annual installments beginning on January 15, 2027, subject to the Reporting Person's continued service as of each such vesting date. |
| 2 | Derivative | Stock Option (Right to Buy) | 2026-03-02 | A | A | 112,661 | $0.00 | 112,661 | D | $6.14 · — to 2036-03-02 | 112,661 Common Stock | (F2) The shares underlying this option vest as follows: 25% of the shares vest on February 1, 2027 with the remainder vesting thereafter pro-rata in 36 monthly installments, subject to the Reporting Person's continued service as of each such vesting date. |